The Takeda and Access Industries-backed oncology therapeutics developer is targeting an offering on the Nasdaq Global Market having previously raised $190m.
Day One Biopharmaceuticals, a US-based cancer drug developer which counts conglomerate Access Industries and pharmaceutical firm Takeda as investors, has filed to raise $100m in an initial public offering.
Founded in 2018, Day One was incubated by venture capital firm Canaan and is developing drug treatments for cancer patients of all ages, with an initial focus on children.
The company’s lead product candidate, DAY101, is being developed to treat progressive low-grade glioma, which Day One claims is the most…
